OB 00X
Alternative Names: FAST-PLV FST gene therapy; Follistatin (FST) gene therapy - Oisin Biotechnologies; FST gene therapy; OB-00XLatest Information Update: 17 Sep 2024
At a glance
- Originator Entos Pharmaceuticals
- Developer Oisin Biotechnologies
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 10 Sep 2024 Pharmacodynamics data from a preclinical trial in Muscle loss released by Oisin Biotechnologies
- 30 Aug 2024 Preclinical trials in Unspecified in Canada (unspecified route), prior to August 2204 (Entos Pharmaceuticals pipeline August 2024)
- 30 Aug 2024 Preclinical trials in Unspecified in USA (unspecified route), prior to August 2204 (Entos Pharmaceuticals pipeline August 2024)